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Introduction. Malignant Pleural Mesothelioma (MPM) is a rare disease, even less frequently described in minority patients. We
used a large population-based dataset to study the role of race in MPM presentation, treatment, and survival. Methods. All cases of
pathologically proven MPM were identified in the Surveillance, Epidemiology, and End Results (SEER) database. Age, sex, diagnosis
year, stage, cancer-directed surgery, radiation, and vital status were analyzed according to self-reported race (black or white). Results.
There were 13,046 white and 688 black MPM patients (incidence: 1.1 per 100,000 whites; 0.5 per 100,000 blacks; age-adjusted,
𝑝 = 0.01). Black patients were more likely to be female, younger, and with advanced stage and less likely to undergo cancerdirected surgery than whites, after adjustment by stage. On multivariable analysis, younger age and having surgery were associated
with longer survival for both cohorts; female gender (HR 0.82 (0.77–0.88)) and early stage at diagnosis (HR 0.83 (0.76–0.90)) were
predictive of longer survival in white, but not in black, patients. Conclusions. Surgery was associated with improved survival for
both black and white MPM patients. However, black patients were less likely to undergo cancer-directed surgery. Increased surgical
intervention in MPM black patients with early stage disease may improve their survival.

1. Introduction
Malignant Pleural Mesothelioma (MPM) is an aggressive
form of asbestos-related cancer with poor prognosis [1].
Possible treatments include surgery, chemotherapy, and radiation or a combination of them, but the effectiveness of
these approaches is still debated. A randomized controlled
trial conducted in the UK to assess the effectiveness of extra
pleural pneumonectomy in terms of survival, complications,
and quality of life [2] suggested that surgery did not offer any
survival advantage in comparison to chemotherapy alone. To
date, however, no US study has evaluated MPM incidence,
treatment, and outcomes in African American patients. There
are two recently published studies on MPM outcome based
on SEER data. One series [3] reported survival in relation
to histology and treatment but did not stratify or otherwise
evaluate the data by race; the other analysis [4], conducted
on a small sample of 294 black MPM patients, suggested

that a smaller proportion of black patients received cancerdirected surgery, while the overall survival was comparable
to that of white patients. This finding suggests that predictors
of survival differ for black and white patients [4] and that
the ethnic discrepancy in surgery rates may reflect a complex
interaction between patients and/or surgeon choices, as well
as clinical factors at diagnosis.
The present analysis of the SEER database was conducted
to assess the incidence and temporal trends of MPM in a
large population-based sample of black patients, to determine
the rates of cancer-directed surgery and radiotherapy and if
choice of treatment influenced survival in this population.

2. Material and Methods
The SEER database was explored from 1973 to 2009 to identify
all cases of pathologically proven MPM within the site recode
ICD-O-3 variable by ICD-O-3 morphology.
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2.1. Definition of Staging. Definition of staging is as follows: localized: invasive tumor confined to pleura; ipsilateral parietal and/or visceral pleura; mesothelioma with
nodules beneath the visceral pleural surface; and localized, not otherwise specified; regional: extension to adjacent
organs/structure: adjacent connective tissue, pericardium,
endothoracic fascia, and diaphragm; visceral pleural invasion
into lung parenchyma, lung involvement not otherwise specified; extension to adjacent organs such as the chest wall, ribs,
myocardium, mediastinal organs, and tissues; mesothelioma
with malignant pleural fluid/effusion; regional ipsilateral
lymph nodes; and regional not otherwise specified; distant:
contralateral pleura and lung, extension to intra-abdominal
organs, cervical tissues, peritoneum, and metastasis; further
contiguous extension; unknown if extension or metastasis;
and distant lymph nodes.
2.2. Definition of Cancer-Directed Surgery. For cases diagnosed after 1998, patients were identified as having received
cancer-directed surgery if any of the following codes were
present for the “Rx Summ-Surg Prim Site” variable: 30 = simple/partial surgical removal of primary site; 40 = total surgical
removal of primary site, enucleation; 50 = “debulking”; 60 =
radical surgery which included partial or total removal of the
primary site in continuity (partial or total removal) with other
organs.
For cases prior to 1998, patients were identified as having
received cancer-directed surgery if any of the following
codes were present for the “Site Specific Surgery” variable: 10 = local surgical excision or destruction of lesion;
20 = partial/wedge/segmental resection; 30, 40 = lobectomy/bilobectomy with/without dissection of lymph nodes;
50 = complete/total/standard pneumonectomy, pneumonectomy, NOS; 60 = radical pneumonectomy plus dissection of
mediastinal lymph nodes; 70 = extended radical pneumonectomy with diaphragm plus lymph nodes; 80 = surgery of
regional and/or distant site(s)/node(s) only (includes removal
of mediastinal mass only); 90 = resection of lung, not
otherwise specified; surgery, not otherwise specified.
For all cases, code 00 (which indicated “no surgical
procedure had been performed”) and the codes for other
types of surgery (codes 01, 02, 03, 04, and 05) were used
to categorize patients who did not undergo cancer-directed
surgery.
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Cases who were diagnosed at age below 18 years, postmortem cases, nonmicroscopically confirmed cases, any living case without survival time in the database, and cases
of malignant mesothelioma of other sites (retroperitoneal,
peritoneal, genital, heart, mediastinum, soft tissue, digestive,
other, and unknown primary site) were excluded. The SEER
09 registry includes data from 9 US registries, from 1973 to
2004; the SEER 17 registry includes cases from 17 registries,
from 2000 to 2004; the SEER 18 registry includes cases from
greater Georgia from 2000 onward, with the exception of
adjustments for the areas impacted by Hurricanes Katrina
and Rita.
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Figure 1: Age-adjusted incidence rates for blacks and whites, 1973–
2009 (note: cases from SEER 9 database are included).

2.3. Statistical Analysis. Age, sex, diagnosis year, stage,
cancer-directed surgery, radiation, and vital status were
analyzed (chemotherapy data not available) according to
self-reported race (black and white). Comparisons between
black and white patients were performed using the 𝑡-test for
continuous variables and chi-square for categorical variables.
Overall survival was defined as the time between initial date
of diagnosis and either date of death or date of last follow up,
whichever came first. Comparison of survival between blacks
and whites was performed using multivariable regression
methods based on a Cox proportional hazards model. All
analyses were performed using SAS version 9.2 (Cary, NC,
USA).

3. Results
MPM age-adjusted incidence rates were 1.1 per 100,000 in
whites and 0.5 per 100,000 in blacks (𝑝 = 0.01). The
significant difference in rates has been present since 1973,
when the data recording started (Figure 1). There were 13,046
white and 688 black patients with pathologic diagnosis of
MPM (Table 1). Black patients were more likely to be female
(26% versus 22%, 𝑝 = 0.01) and younger (67 versus 70,
𝑝 < 0.0001) and to present with more advanced stage of
disease (65% versus 59%, 𝑝 = 0.002).
3.1. Therapy. Black patients were less likely to receive cancerdirected surgery than white patients (18% versus 24%, 𝑝 =
0.001). Black patients were more likely than whites to
undergo no surgery or radiation (73% versus 68% received
no treatment; 𝑝 = 0.005). There was an inverse trend
in undergoing surgery with more advanced stage in both
ethnicities: among whites, 31.5% of localized cases received
surgery, versus 21.4% of the advanced stage white patients.
Among black patients, the corresponding proportions were
29.3% for localized disease and 15.1% for advanced stages
(Table 3).
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Table 1: Patient, disease, and treatment characteristics among whites and blacks (𝑛 = 13734).

Variable

Categories
Male
Female

Sex
Mean age in year (95% CI)

Localized
Regional
Distant
Unknown
No
Yes
No
Yes
No
Surgery only
Radiation only
Both surgery and radiation

Overall stage

Cancer-directed surgery
Radiation

Therapy

Mean survival in months (95% CI)

Whites (𝑛 = 13046)
10159 (78%)
2887 (22%)
70.2 (70.0–70.4)
1449 (11%)
2155 (16%)
7639 (59%)
1803 (14%)
9959 (76%)
3087 (24%)
11387 (87%)
1659 (13%)
8933 (68%)
2454 (19%)
1026 (8%)
633 (5%)
15.5 (15.1–15.9)

Blacks (𝑛 = 688)
507 (74%)
181 (26%)
66.6 (65.6–67.6)
75 (11%)
91 (13%)
450 (65%)
72 (11%)
563 (82%)
125 (18%)
611 (89%)
77 (11%)
505 (73%)
106 (15%)
58 (9%)
19 (3%)
16.7 (14.5–19.0)

𝑝 value
0.010
<0.0001
0.002

0.001
0.241

0.005

0.899

SEER, Surveillance, Epidemiology, and End Results.

Table 2: Effect of patient, disease, and treatment characteristics on 5-year survival (𝑛 = 13734).
Categories

Whites
adjusted HR
(95% CI)∗

Blacks
adjusted HR
(95% CI)∗

Sex

Male/female

0.82 (0.77–0.88)

1.10 (0.84–1.44)

Age

Per year decrease

0.81 (0.79–0.83)

0.76 (0.68–0.83)

Stage

Localized
Regional
Distant
Unknown

1.0 (ref.)
1.26 (1.13–1.39)
1.21 (1.11–1.31)
1.11 (0.98–1.25)

1.0 (ref.)
0.98 (0.61–1.59)
1.14 (0.77–1.67)
0.80 (0.44–1.45)

Cancer-directed surgery

No/yes

0.65 (0.61–0.70)

0.53 (0.38–0.73)

Radiation

No/yes

1.10 (1.01–1.20)

1.24 (0.81–1.89)

None
Surgery only
Radiation only
Both surgery and radiation

1.0 (ref.)
0.68 (0.64–0.73)
1.27 (1.13–1.42)
0.63 (0.55–0.71)

1.0 (ref.)
0.53 (0.37–0.74)
1.24 (0.75–2.04)
0.65 (0.30–1.39)

Variable

Therapy

∗

Adjusted for the other variables in the table.

3.2. Survival. Overall survival was similar for black and white
patients (Figure 2). On multivariable analysis, female gender,
younger age, early stage, and cancer-directed surgery were
independent predictors of longer survival in white patients;
younger age and surgery were associated with longer survival
in black patients (Table 2). Three- and 5-year survival for
patients who did not receive treatment was 7.9% and 3.5%,
respectively, in whites and 10.6% and 6.7% in blacks.

4. Discussion
This SEER analysis includes the largest sample of black
patients with MPM to date and demonstrates that MPM
incidence is significantly lower in blacks compared to

whites. Reasons for this large difference may reside in the
lower opportunity for occupational asbestos exposure among
blacks. The U.S. Department of Labor periodically publishes
summary statistics on the US workforce [5] and reports that
black workers are highly represented in the health and education services, public administration, and transportation,
while they are less likely to be employed in those occupations
where asbestos has been used in the past, such as building and
ship construction, insulation, and mining. In addition, fewer
blacks served in the U.S. Navy, which was historically a source
of asbestos exposure for many men [6, 7]. The observation
that there is a higher proportion of women among black
(compared to white) MPM patients is a new finding and
warrants further investigation. Blacks are also diagnosed with
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Table 3: Receipt of surgery by stage among blacks and whites (𝑛 = 13734).
Whites
Surgery performed

Summary stage

Localized
Regional
Distant
Unknown

No
𝑁 (%)

Yes
𝑁 (%)

No
𝑁 (%)

Yes
𝑁 (%)

992 (68.5)
1346 (62.4)
6002 (78.6)
1619 (89.8)

457 (31.5)
809 (37.5)
1637 (21.4)
184 (10.2)

53 (70.7)
61 (67.0)
382 (84.9)
67 (93.0)

22 (29.3)
30 (33.0)
68 (15.1)
5 (7.0)

Kaplan-Meier survival estimates
1.00
0.75
0.50
0.25
0.00
0

12

36

24

48

Blacks
Surgery performed

60

Months
Whites
Blacks

Figure 2: MPM survival according to ethnicity, 1973–2009. Logrank chi-square: 0.45; 𝑝 value 0.5012; Wilcoxon test: 4.13; 𝑝 value
0.042.

MPM at an earlier age than whites, which could reflect earlier
exposure to asbestos than whites or alternatively may reflect
more aggressive disease with earlier clinical symptoms.
Black MPM patients are diagnosed at a later stage than
white patients; this may be due to general delays in seeking
care for medical symptoms, lack of access to diagnostic
procedures, lack of timely diagnosis when symptoms occur,
lack of access to appropriate medical care, and/or lack of
availability of insurance coverage. Another possible factor
could be that symptoms at MPM onset are different in black
compared to white patients, as previously reported in lung
cancer [8], and this could cause delay in diagnosis. The role
of each of these factors cannot be elucidated in this study, as
the information is not available in the SEER database.
When the therapeutic approach is analyzed according
to ethnicity, black patients underwent less cancer-directed
surgery than white patients, as suggested by previous analysis
of a smaller SEER dataset [4]. Similar to the observed lower
rates of cancer-directed surgery in black MPM patients, a
study conducted in early stage non-small cell lung cancer
[9] demonstrated a low rate of surgical treatment among
blacks. Black MPM patients were less likely to undergo
either surgery or radiation in comparison to white patients.
Although late stage at diagnosis was thought to be the main
reason for this difference in treatment with regard to race, the
stratified analysis by stage does not support that hypothesis,

as blacks underwent less cancer-directed surgery than whites
at every stage of MPM. Reasons for less surgical treatment
could be the presence of comorbidities in black patients at
the time of MPM diagnosis or the fact that patients were
diagnosed in community-based hospitals lacking adequate
surgical expertise or that surgery was not considered to be
a treatment option. A recently published paper [10] indicates
that race disparities exist in access to high-volume hospitals,
a proxy for better quality of care in complex cases [11], even
after adjustment for socioeconomic and insurance status.
When performed, cancer-directed surgery was associated
with higher survival in both ethnic groups. Unfortunately, we
were not able to analyze what type of surgical approach was
performed (extrapleural pneumonectomy or radical pleurectomy/decortication) or if the approach differed according to
ethnicity. Another limitation of the SEER dataset is that it
does not contain information on any chemotherapy regimen
administered to the patients. Other limitations include the
broad definition of stage and the limited quality of the
histology classification. Differences in these variables may
have contributed to the observed health care disparities in
rates of cancer-directed surgery, for example, if a higher
proportion of blacks had nonepithelial (less favorable celltype) disease compared to whites. However, the use of the
SEER database allowed us to conduct the largest study, to our
knowledge, of MPM black patients.
This analysis indicates that black patients with MPM are
treated less frequently with surgery than their white counterparts, at every stage of their disease, but they experience
similar survival as white MPM patients. This suggests that
further attention to the treatment of black patients with
MPM is needed to determine if black MPM patient survival
would be improved with better access to the same treatments
as whites. Further studies on exposure history, access to
care, type of medical and surgical treatment, and hospital
characteristics in black patients with MPM are needed.
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